ROPER JESS 4

What Happened Jess Roper, a director of Revelation Biosciences, sold 1,591 shares on February 3, 2026 to satisfy tax withholding obligations related to vested restricted stock. The shares were disposed at a weighted-average price of $1.85, resulting in proceeds of approximately $2,943. This was a mandatory tax-withholding sale (not a voluntary or investment-motivated sale).

Key Details

• Date of transaction: 2026-02-03; Form 4 filed 2026-02-05 (timely filing).
• Transaction type/code: F — payment of exercise price or tax liability (tax-withholding sale).
• Shares sold: 1,591; weighted-average price reported $1.85; reported price range $1.84–$1.88.
• Amount realized: ~$2,943.
• Shares owned after transaction: Not specified in the filing.
• Notable footnotes:
  • F1: All share counts reflect a 1-for-4 reverse split effective Jan 28, 2026.
  • F2: Shares were sold by the issuer solely to satisfy required tax obligations upon vesting of restricted stock awards; sale was mandatory and not at the reporting person's discretion.
  • F3: Weighted-average price; reporting person can provide breakdown of shares sold at each price upon request.

Context This was a mandatory, administrative sale to cover tax liabilities from vesting (common for restricted stock awards) and does not necessarily signal the director's view of the company's prospects. For retail investors, purchases or voluntary sales typically carry more interpretive weight than mandatory tax-withholding dispositions.